TY - JOUR
T1 - Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry
AU - Gaggiano, Carla
AU - Maselli, Anna
AU - Sfikakis, Petros P.
AU - Laskari, Katerina
AU - Ragab, Gaafar
AU - Hegazy, Mohamed Tharwat
AU - Laymouna, Ahmed Hatem
AU - Lopalco, Giuseppe
AU - Almaghlouth, Ibrahim A.
AU - Asfina, Kazi Nur
AU - Alahmed, Ohoud
AU - Giardini Mayrink, Henrique Ayres
AU - Parente De Brito Antonelli, Isabele
AU - Cattalini, Marco
AU - Piga, Matteo
AU - Sota, Jurgen
AU - Gentileschi, Stefano
AU - Maggio, Maria Cristina
AU - Opris-Belinski, Daniela
AU - Hatemi, Gülen
AU - Insalaco, Antonella
AU - Olivieri, Alma Nunzia
AU - Tufan, Abdurrahman
AU - Karadeniz, Hazan
AU - Kardaş, Riza Can
AU - La Torre, Francesco
AU - Cardinale, Fabio
AU - Marino, Achille
AU - Guerriero, Silvana
AU - Ruscitti, Piero
AU - Tarsia, Maria
AU - Vitale, Antonio
AU - Caggiano, Valeria
AU - Telesca, Salvatore
AU - Iannone, Florenzo
AU - Parretti, Veronica
AU - Frassi, Micol
AU - Aragona, Emma
AU - Ciccia, Francesco
AU - Wiesik-Szewczyk, Ewa
AU - Ionescu, Ruxandra
AU - Şahin, Ali
AU - Akkoç, Nurullah
AU - Hinojosa-Azaola, Andrea
AU - Tharwat, Samar
AU - Hernández-Rodríguez, José
AU - Espinosa, Gerard
AU - Conti, Giovanni
AU - Del Giudice, Emanuela
AU - Govoni, Marcello
AU - Emmi, Giacomo
AU - Fabiani, Claudia
AU - Balistreri, Alberto
AU - Frediani, Bruno
AU - Rigante, Donato
AU - Cantarini, Luca
PY - 2023
Y1 - 2023
N2 - This study aims to describe musculoskeletal manifestations (MSM) in children with Behçet’s syndrome (BS), their association with other disease manifestations, response to therapy, and long-term prognosis. Data were retrieved from the AIDA Network Behçet’s Syndrome Registry. Out of a total of 141 patients with juvenile BS, 37 had MSM at disease onset (26.2%). The median age at onset was 10.0 years (IQR 7.7). The median follow-up duration was 21.8 years (IQR 23.3). Recurrent oral (100%) and genital ulcers (67.6%) and pseudofolliculitis (56.8%) were the most common symptoms associated with MSM. At disease onset, 31 subjects had arthritis (83.8%), 33 arthralgia (89.2%), and 14 myalgia (37.8%). Arthritis was monoarticular in 9/31 cases (29%), oligoarticular in 10 (32.3%), polyarticular in 5 (16.1%), axial in 7 (22.6%). Over time, arthritis became chronic-recurrent in 67.7% of cases and 7/31 patients had joint erosions (22.6%). The median Behçet's Syndrome Overall Damage Index was 0 (range 0–4). Colchicine was inefcacious for MSM in 4/14 cases (28.6%), independently from the type of MSM (p=0.46) or the concomitant therapy (p=0.30 for cDMARDs, p=1.00 for glucocorticoids); cDMARDs and bDMARDs were inefcacious for MSM in 6/19 (31.4%) and 5/12 (41.7%) cases. The presence of myalgia was associated with bDMARDs inefcacy (p=0.014). To conclude, MSM in children with BS are frequently associated with recurrent ulcers and pseudofolliculitis. Arthritis is mostly mono- or oligoarticular, but sacroiliitis is not unusual. Prognosis of this subset of BS is overall favorable, though the presence of myalgia negatively afects response to biologic therapies.
AB - This study aims to describe musculoskeletal manifestations (MSM) in children with Behçet’s syndrome (BS), their association with other disease manifestations, response to therapy, and long-term prognosis. Data were retrieved from the AIDA Network Behçet’s Syndrome Registry. Out of a total of 141 patients with juvenile BS, 37 had MSM at disease onset (26.2%). The median age at onset was 10.0 years (IQR 7.7). The median follow-up duration was 21.8 years (IQR 23.3). Recurrent oral (100%) and genital ulcers (67.6%) and pseudofolliculitis (56.8%) were the most common symptoms associated with MSM. At disease onset, 31 subjects had arthritis (83.8%), 33 arthralgia (89.2%), and 14 myalgia (37.8%). Arthritis was monoarticular in 9/31 cases (29%), oligoarticular in 10 (32.3%), polyarticular in 5 (16.1%), axial in 7 (22.6%). Over time, arthritis became chronic-recurrent in 67.7% of cases and 7/31 patients had joint erosions (22.6%). The median Behçet's Syndrome Overall Damage Index was 0 (range 0–4). Colchicine was inefcacious for MSM in 4/14 cases (28.6%), independently from the type of MSM (p=0.46) or the concomitant therapy (p=0.30 for cDMARDs, p=1.00 for glucocorticoids); cDMARDs and bDMARDs were inefcacious for MSM in 6/19 (31.4%) and 5/12 (41.7%) cases. The presence of myalgia was associated with bDMARDs inefcacy (p=0.014). To conclude, MSM in children with BS are frequently associated with recurrent ulcers and pseudofolliculitis. Arthritis is mostly mono- or oligoarticular, but sacroiliitis is not unusual. Prognosis of this subset of BS is overall favorable, though the presence of myalgia negatively afects response to biologic therapies.
KW - Autoinflammation
KW - Behçet's disease
KW - Autoinflammation
KW - Behçet's disease
UR - http://hdl.handle.net/10807/232827
U2 - 10.1007/s11739-023-03215-w
DO - 10.1007/s11739-023-03215-w
M3 - Article
SN - 1828-0447
VL - 18
SP - 743
EP - 754
JO - Internal and Emergency Medicine
JF - Internal and Emergency Medicine
ER -